Sonnet BioTherapeutics regains compliance with Nasdaq

seekingalpha10-17

Sonnet BioTherapeutics Holdings (NASDAQ:SONN) has regained compliance with the bid price requirement in Listing Rule 5550(a)(2) for continued listing on the Nasdaq Capital Market. The Co.’s securities...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2476105768?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-10-17 23:17","share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","id":"2476105768","market":"us","top_or_hot":-1,"title":"Sonnet BioTherapeutics regains compliance with Nasdaq","media":"seekingalpha","content":"<div>\n<p>Sonnet BioTherapeutics Holdings (NASDAQ:SONN) has regained compliance with the bid price requirement in Listing Rule 5550(a)(2) for continued listing on the Nasdaq Capital Market. The Co.’s securities...</p>\n\n<a href=\"https://seekingalpha.com/news/4170398-sonnet-biotherapeutics-regains-compliance-with-nasdaq\">Source Link</a>\n\n</div>\n","source":"seekingalpha","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sonnet BioTherapeutics regains compliance with Nasdaq</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSonnet BioTherapeutics regains compliance with Nasdaq\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-10-17 23:17 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/4170398-sonnet-biotherapeutics-regains-compliance-with-nasdaq><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Sonnet BioTherapeutics Holdings (NASDAQ:SONN) has regained compliance with the bid price requirement in Listing Rule 5550(a)(2) for continued listing on the Nasdaq Capital Market. The Co.’s securities...</p>\n\n<a href=\"https://seekingalpha.com/news/4170398-sonnet-biotherapeutics-regains-compliance-with-nasdaq\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://seekingalpha.com/news/4170398-sonnet-biotherapeutics-regains-compliance-with-nasdaq","article_id":"2476105768","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2476105768","pubTimestamp":1729178238,"sourceInfo":{"source_id":"seekingalpha","name":"Seeking Alpha"},"weMediaInfo":null,"summary":"Sonnet BioTherapeutics Holdings  hasregained compliance with the bid price requirement in Listing Rule 5550 for continued listing on the Nasdaq Capital Market. The Co.’s securities may be delisted from Nasdaq if, within one-year monitoring period, the Nasdaq finds the Co. again out of compliance with the Bid Price Rule 5810.","collect":0,"end_time":0,"defaultTopTitle":"seekingalpha.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","SONN":"Sonnet BioTherapeutics Holdings, Inc."},"translate_title":"Sonnet BioTherapeutics重新遵守纳斯达克","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SONN":0.9},"content_text":"Sonnet BioTherapeutics Holdings (NASDAQ:SONN) has regained compliance with the bid price requirement in Listing Rule 5550(a)(2) for continued listing on the Nasdaq Capital Market. The Co.’s securities may be delisted from Nasdaq if, within one-year monitoring period, the Nasdaq finds the Co. again out of compliance with the Bid Price Rule 5810(c)(2).\nSONN shares +17.6% to $5.98.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2476105768"}